Using novel AI technology, this study identifies two bioactive ingredients (NCT and NFT) that demonstrated promising effects on gut barrier integrity in laboratory settings. To evaluate whether these effects could be replicated in humans, a clinical trial was conducted.
Gut barrier function is crucial for overall health. Poor integrity—often referred to as “leaky gut”—is associated with both gastrointestinal and systemic conditions. Emerging evidence suggests that impaired gut barrier function is prevalent in individuals with IBS-D and may contribute to symptom severity. Currently, there is limited clinical evidence supporting products that improve gut barrier function, especially non-pharmaceutical options for IBS-D. This study aimed to assess whether NCT and NFT could improve gut barrier function and alleviate symptoms in IBS-D patients.
Type of trial: Double-blind, randomised controlled trial
Sample size and population: 32 participants meeting ROME IV criteria for IBS-D
Duration and intervention:
2-week screening period
3-week intervention with either NCT/NFT or placebo, taken once daily
Change in gut barrier integrity assessed via the lactulose:mannitol gut permeability test
Blood-based biomarkers: LPS, LBP, Zonulin, CD14, and LCN2
IBS symptom severity using the validated IBS-SSS questionnaire
Stool frequency, consistency, and daily symptom scores via bowel diaries
Safety assessment
Statistically significant improvement in gut barrier integrity in the active group vs. placebo
Significant reduction in abdominal bloating in the active group vs. placebo
Greater reduction in total IBS-SSS scores in the active group compared to placebo
The study was published in a peer-reviewed journal. The clinical evidence supports the product’s positioning as a supplement that helps reduce digestive symptoms and maintain gut barrier integrity.